Major improvements in supportive therapies and the development of CFTR targeted therapies increased life expectancy in CF patients to a median survival of 40 years or more in industrialized nations (Dodge et al., 2007; MacKenzie et al., 2014). The gene discussed is CFTR; the disease is cystic fibrosis.